EUROpean Endeavour for Chimeric Antigen Receptor Therapies

Fact Sheet

Project Information

<table>
<thead>
<tr>
<th>EURE-CART</th>
<th>Funded under H2020-EU.3.1.3.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant agreement ID: 733297</td>
<td>Overall budget € 5 903 146</td>
</tr>
<tr>
<td>Project website [icon]</td>
<td>EU contribution € 5 903 146</td>
</tr>
<tr>
<td>Status</td>
<td>Coordinated by</td>
</tr>
<tr>
<td>Ongoing project</td>
<td>MOLECULAR MEDICINE SPA</td>
</tr>
<tr>
<td>Start date</td>
<td>Italy</td>
</tr>
<tr>
<td>1 January 2017</td>
<td></td>
</tr>
<tr>
<td>End date</td>
<td></td>
</tr>
<tr>
<td>31 December 2020</td>
<td></td>
</tr>
</tbody>
</table>

Objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy, to combine scientific and medical knowledge and push EU to the forefront of CAR T-cell immunotherapy.
therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

Field of science

/medical and health sciences/basic medicine/immunology/immunotherapy
/medical and health sciences/medical biotechnology/genetic engineering/gene therapy
/medical and health sciences/clinical medicine/oncology/cancer
/medical and health sciences/clinical medicine/oncology

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-2016-RTD

Funding Scheme

RIA - Research and Innovation action

Coordinator

MOLECULAR MEDICINE SPA

Address
Via Olgettina 58
20132 Milano
Italy

Activity type
Private for-profit entities
(excluding Higher or Secondary Education Establishments)

EU contribution
€ 1 994 575

Website Contact the organisation
<table>
<thead>
<tr>
<th>Organisation Name</th>
<th>Country</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSPEDALE SAN RAFFAELE SRL</td>
<td>Italy</td>
<td>€ 1,112,500</td>
<td>Via Olgettina 60 20132 Milano</td>
<td>Private for-profit entities (excluding Higher or Secondary Education Establishments)</td>
</tr>
<tr>
<td>UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT</td>
<td>Germany</td>
<td>€ 856,076.25</td>
<td>Josef-schneider-strasse 2 97080 Wurzburg</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
<tr>
<td>OSPEDALE PEDIATRICO BAMBINO GESU</td>
<td>Italy</td>
<td>€ 492,431.25</td>
<td>Piazza Sant Onofrio 4 00165 Roma</td>
<td>Other</td>
</tr>
<tr>
<td>FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU</td>
<td>Spain</td>
<td>€ 225,011</td>
<td></td>
<td>Research Organisations</td>
</tr>
</tbody>
</table>
Calle Sant Antoni M Claret 167
08025 Barcelona

Website  
Contact the organisation

Research Organisations

FAKULTNI NEMOCNICE OSTRAVA

Czechia
EU contribution
€ 224 552,50

Address
Activity type
17 Listopadu 1790
708 52 Ostrava Poruba
Research Organisations

Website  
Contact the organisation

ISTITUTO SUPERIORE DI SANITA

Italy
EU contribution
€ 225 000

Address
Activity type
Viale Regina Elena 299
00161 Roma
Research Organisations

Website  
Contact the organisation

ACROMION GMBH

Germany
EU contribution
€ 398 000

Address
Activity type
Europaallee 27-29
50226 Frechen
Private for-profit entities
(excluding Higher or Secondary Education Establishments)

Contact the organisation

ARTTIC

France
EU contribution
€ 375 000

Address
Activity type